To further explore the expression pattern of ISG20 in glioma, we analyzed the expression of ISG20 in patient subgroups with disparate clinical characteristics, including age, gender, IDH mutation, 1p19q co-deletion, MGMT methylation, WHO grade, histology, and primary therapy outcome. This evidence concerns the gene ISG20 and central nervous system cancer.